Cathepsin E, Maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer

American Journal of Pathology

Volumn 180, Issue 5, 2012, Pages 1824-1834

  Fristrup, Niels ^a   Ulhøi, Benedicte P ^a   Birkenkamp Demtrder, Karin ^a   Mansilla, Francisco ^a   Sanchez Carbayo, Marta ^b   Segersten, Ulrika ^c   Malmstrm, Per Uno ^c   Hartmann, Arndt ^d   Palou, Joan ^e   Alvarez Mgica, Miguel ^f   Zieger, Karsten ^a   Borre, Michael ^a   Ørntoft, Torben F ^a   Dyrskjøt, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e FUNDACIÓ PUIGVERT   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN E; MASPIN; POLO LIKE KINASE 1; SURVIVIN;

ANTIBODY SPECIFICITY; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SPAIN; STANDARD; SWEDEN; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; VALIDATION STUDY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN E; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SERPINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84860244341     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.01.023     Document Type: Article

References (43)

1. A. Jemal, R. Siegel, J. Xu, E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. L.A. Kiemeney, J.A. Witjes, A.L. Verbeek, R.P. Heijbroek, F.M. Debruyne The clinical epidemiology of superficial bladder cancer Dutch South-East Cooperative Urological Group Br J Cancer 67 1993 806 812
3. M.S. Cookson, H.W. Herr, Z.F. Zhang, S. Soloway, P.C. Sogani, W.R. Fair The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62 67
4. L. Cheng, J.C. Cheville, R.M. Neumann, B.C. Leibovich, K.S. Egan, B.E. Spotts, D.G. Bostwick Survival of patients with carcinoma in situ of the urinary bladder Cancer 85 1999 2469 2474
5. B. Ehdaie, D. Theodorescu Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis Expert Rev Anticancer Ther 8 2008 1103 1110
6. Y.M. Hong, K.R. Loughlin Economic impact of tumor markers in bladder cancer surveillance Urology 71 2008 131 135
7. R.J. Sylvester, A.P. van der Meijden, W. Oosterlinck, J.A. Witjes, C. Bouffioux, L. Denis, D.W. Newling, K. Kurth Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 475
8. L. Dyrskjot Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics Expert Rev Mol Diagn 3 2003 635 647
9. L. Dyrskjot, K. Zieger, F.X. Real, N. Malats, A. Carrato, C. Hurst, S. Kotwal, M. Knowles, P.U. Malmstrom, M. de la Torre, K. Wester, Y. Allory, D. Vordos, A. Caillault, F. Radvanyi, A.M. Hein, J.L. Jensen, K.M. Jensen, N. Marcussen, T.F. Orntoft Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study Clin Cancer Res 13 2007 3545 3551
10. E. Blaveri, J.P. Simko, J.E. Korkola, J.L. Brewer, F. Baehner, K. Mehta, S. Devries, T. Koppie, S. Pejavar, P. Carroll, F.M. Waldman Bladder cancer outcome and subtype classification by gene expression Clin Cancer Res 11 2005 4044 4055
11. L. Dyrskjot, K. Zieger, M. Kruhoffer, T. Thykjaer, J.L. Jensen, H. Primdahl, N. Aziz, N. Marcussen, K. Moller, T.F. Orntoft A molecular signature in superficial bladder carcinoma predicts clinical outcome Clin Cancer Res 11 2005 4029 4036
12. T.F. Orntoft, T. Thykjaer, F.M. Waldman, H. Wolf, J.E. Celis Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas Mol Cell Proteomics 1 2002 37 45
13. J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, J. Torhorst, M.J. Mihatsch, G. Sauter, O.P. Kallioniemi Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 1998 844 847
14. S. Heeboll, M. Borre, P.D. Ottosen, C.L. Andersen, F. Mansilla, L. Dyrskjot, T.F. Orntoft, N. Torring SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation Histol Histopathol 23 2008 1069 1076
15. K. Soreide Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research J Clin Pathol 62 2009 1 5
16. A.B. Als, L. Dyrskjot, H. von der Masse, K. Koed, F. Mansilla, H.E. Toldbod, J.L. Jensen, B.P. Ulhoi, L. Sengelov, K.M. Jensen, T.F. Orntoft Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer Clin Cancer Res 13 2007 4407 4414
17. F. Mansilla, K. Birkenkamp-Demtroder, M. Kruhoffer, F.B. Sorensen, C.L. Andersen, P. Laiho, L.A. Aaltonen, H.W. Verspaget, T.F. Orntoft Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups Br J Cancer 96 2007 1896 1903
18. F.E. Harrell Jr., R.M. Califf, D.B. Pryor, K.L. Lee, R.A. Rosati Evaluating the yield of medical tests JAMA 247 1982 2543 2546
19. J. Fernandez-Gomez, R. Madero, E. Solsona, M. Unda, L. Martinez-Pineiro, A. Ojea, J. Portillo, M. Montesinos, M. Gonzalez, C. Pertusa, J. Rodriguez-Molina, J.E. Camacho, M. Rabadan, A. Astobieta, S. Isorna, P. Muntanola, A. Gimeno, M. Blas, J.A. Martinez-Pineiro The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables Eur Urol 60 2011 423 430
20. M.S. Pepe, Z. Feng, H. Janes, P.M. Bossuyt, J.D. Potter Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design J Natl Cancer Inst 100 2008 1432 1438
21. T. Kawakubo, K. Okamoto, J. Iwata, M. Shin, Y. Okamoto, A. Yasukochi, K.I. Nakayama, T. Kadowaki, T. Tsukuba, K. Yamamoto Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surface Cancer Res 67 2007 10869 10878
22. M. Shin, T. Kadowaki, J. Iwata, T. Kawakubo, N. Yamaguchi, R. Takii, T. Tsukuba, K. Yamamoto Association of cathepsin E with tumor growth arrest through angiogenesis inhibition and enhanced immune responses Biol Chem 388 2007 1173 1181
23. T. Thykjaer, C. Workman, M. Kruhoffer, K. Demtroder, H. Wolf, L.D. Andersen, C.M. Frederiksen, S. Knudsen, T.F. Orntoft Identification of gene expression patterns in superficial and invasive human bladder cancer Cancer Res 61 2001 2492 2499
24. P.J. Wild, A. Herr, C. Wissmann, R. Stoehr, A. Rosenthal, D. Zaak, R. Simon, R. Knuechel, C. Pilarsky, A. Hartmann Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder Clin Cancer Res 11 2005 4415 4429
25. Z. Zou, A. Anisowicz, M.J. Hendrix, A. Thor, M. Neveu, S. Sheng, K. Rafidi, E. Seftor, R. Sager Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells Science 263 1994 526 529
26. P.A. Pemberton, A.R. Tipton, N. Pavloff, J. Smith, J.R. Erickson, Z.M. Mouchabeck, M.C. Kiefer Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface J Histochem Cytochem 45 1997 1697 1706
27. N. Maass, M. Teffner, F. Rosel, R. Pawaresch, W. Jonat, K. Nagasaki, P. Rudolph Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast J Pathol 195 2001 321 326
28. S. Machtens, J. Serth, C. Bokemeyer, W. Bathke, A. Minssen, C. Kollmannsberger, J. Hartmann, R. Knuchel, M. Kondo, U. Jonas, M. Kuczyk Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features Int J Cancer 95 2001 337 342
29. S.K. Mohsin, M. Zhang, G.M. Clark, A.D. Craig Maspin expression in invasive breast cancer: association with other prognostic factors J Pathol 199 2003 432 435
30. S. Blandamura, E. D'Alessandro, L. Giacomelli, V. Guzzardo, W. Battanello, M. Repele, V. Ninfo Expression of maspin in papillary Ta/T1 bladder neoplasms Anticancer Res 28 2008 471 478
31. M.G. Friedrich, M.I. Toma, S. Petri, J.C. Cheng, P. Hammerer, A. Erbersdobler, H. Huland Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis Eur Urol 45 2004 737 743
32. S. Sugimoto, N. Maass, Y. Takimoto, K. Sato, S. Minei, M. Zhang, Y. Hoshikawa, K.P. Junemann, W. Jonat, K. Nagasaki Expression and regulation of tumor suppressor gene maspin in human bladder cancer Cancer Lett 203 2004 209 215
33. M.J. Duffy, N. O'Donovan, D.J. Brennan, W.M. Gallagher, B.M. Ryan Survivin: a promising tumor biomarker Cancer Lett 249 2007 49 60
34. W. Yin, N. Chen, Y. Zhang, H. Zeng, X. Chen, Y. He, X. Wang, Q. Zhou Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder Mod Pathol 19 2006 1487 1497
35. J.H. Ku, C. Kwak, H.S. Lee, H.K. Park, E. Lee, S.E. Lee Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder J Urol 171 2004 631 635
36. J.A. Karam, Y. Lotan, R. Ashfaq, A.I. Sagalowsky, S.F. Shariat Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder Urology 70 2007 482 486
37. M.A. van Vugt, R.H. Medema Getting in and out of mitosis with Polo-like kinase-1 Oncogene 24 2005 2844 2859
38. K. Ando, T. Ozaki, H. Yamamoto, K. Furuya, M. Hosoda, S. Hayashi, M. Fukuzawa, A. Nakagawara Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation J Biol Chem 279 2004 25549 25561
39. M.R. Smith, M.L. Wilson, R. Hamanaka, D. Chase, H. Kung, D.L. Longo, D.K. Ferris Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase Biochem Biophys Res Commun 234 1997 397 405
40. F. Rodel, S. Keppner, G. Capalbo, R. Bashary, M. Kaufmann, C. Rodel, K. Strebhardt, B. Spankuch Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer Am J Pathol 177 2010 918 929
41. K.V. Gleixner, V. Ferenc, B. Peter, A. Gruze, R.A. Meyer, E. Hadzijusufovic, S. Cerny-Reiterer, M. Mayerhofer, W.F. Pickl, C. Sillaber, P. Valent Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536 Cancer Res 70 2010 1513 1523
42. S. Seth, Y. Matsui, K. Fosnaugh, Y. Liu, N. Vaish, R. Adami, P. Harvie, R. Johns, G. Severson, T. Brown, A. Takagi, S. Bell, Y. Chen, F. Chen, T. Zhu, R. Fam, I. Maciagiewicz, E. Kwang, M. McCutcheon, K. Farber, P. Charmley, M.E. Houston Jr., A. So, M.V. Templin, B. Polisky RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer Mol Ther 19 2011 928 935
43. Y. Yamamoto, H. Matsuyama, S. Kawauchi, H. Matsumoto, K. Nagao, C. Ohmi, S. Sakano, T. Furuya, A. Oga, K. Naito, K. Sasaki Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer Oncology 70 2006 231 237